Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.
Nat Commun. 2021 Dec 22;12(1):7348. doi: 10.1038/s41467-021-26472-9.
Nat Commun. 2021.
PMID: 34937871
Free PMC article.
Clinical Trial.